Cardiovascular risk and the thiazolidinediones: déjà vu all over again?

[1]  Yoon K Loke,et al.  Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. , 2007, JAMA.

[2]  A. Lincoff,et al.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.

[3]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. , 2007, The New England journal of medicine.

[4]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[5]  J. Plutzky,et al.  Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. , 2007, Circulation.

[6]  M. Tonelli,et al.  Surrogate markers in clinical studies: problems solved or created? , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[8]  S. Grundy,et al.  Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association , 2003, Diabetes care.

[9]  Michael J. Goodman,et al.  Contraindicated use of cisapride: impact of food and drug administration regulatory action. , 2000, JAMA.